Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

Trial Profile

A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2019

At a glance

  • Drugs Binimetinib (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms NEMO
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 05 Jul 2019 This trial has been completed in Greece (on 2019-06-04).
    • 05 Jul 2019 This trial has been completed in Hungary (on-2019-06-04).
    • 04 Jul 2019 This trial has been completed in Belgium (on 2019-06-04).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top